Gene Therapy Global Market Opportunities and Strategies to 2032

This report describes and explains the gene therapy market and covers 2017-2022, termed the historic period, and 2022-2027 termed the forecast period, along with further forecasts for the period 2027-2032. The report evaluates the market across each region and for the major economies within each region.

The global gene therapy market reached a value of nearly $7,370.8 million in 2022, having increased at a compound annual growth rate (CAGR) of 15.8% since 2017. The market is expected to grow from $7,370.8 million in 2022 to $24,027.1 million in 2027 at a rate of 26.7%. The market is then expected to grow at a CAGR of 13.4% from 2027 and reach $45,071.9 million in 2032.

Growth in the historic period resulted from rising pharmaceutical R&D expenditure, a rise in public-private partnerships, government investments and rising cases of spinal muscular atrophy. Factors that negatively affected growth in the historic period were off-target specificity, challenges in nucleotide delivery to cells, instability of the nucleotides, challenges due to regulatory changes, low healthcare access, reimbursement challenges and the coronavirus pandemic.

Going forward, an increasing number of cancer cases, a growing aging population, increasing research and development spending in the pharmaceutical sector and a rising focus on gene therapy will drive the market. Factors that could hinder the growth of the gene therapy market in the future include high cost of gene therapy, stringent regulations and the Russia- Ukraine war.

The gene therapy market is segmented by vector into viral vector and non-viral vector. The viral vector was the largest segment of the gene therapy market by vector, accounting for $6,555.7 million or 88.9% of the total market in 2022. It is expected to be the fastest-growing segment going forward at a CAGR of 26.7%.

The gene therapy market is segmented by application into oncology, orphan disease, knee osteoarthritis and neurological disorders. The oncology market was the largest segment of the gene therapy market by application, accounting for $3,258.2 million or 44.2% of the total market in 2022. The neurological disorders market is expected to be the fastest-growing segment going forward at a CAGR of 27.7%.

The gene therapy market is segmented by end users into biopharmaceutical companies, research institutes and other end users. The biopharmaceutical companies was the largest segment of the gene therapy market by end users, accounting for $3,882.7 million or 52.7% of the total market in 2022. The other end users market is expected to be the fastest-growing segment going forward at a CAGR of 27.6%.

The gene therapy market is segmented by gene therapy type into germline therapy and somatic cell therapy. The somatic cell therapy was the largest segment of the gene therapy market by gene therapy type, accounting for $7,002.2 million or 95.0% of the total market in 2022. It is expected to be the fastest-growing segment going forward at a CAGR of 26.7%.

North America was the largest region in the gene therapy market, accounting for 44.6% of the global market in 2022. It was followed by Western Europe, Asia Pacific and the other regions. Going forward, the fastest growing regions in the gene therapy market will be South America and the Middle East, where growth will be at CAGRs of 44.4% and 42.3% respectively from 2022-2027.

The global gene therapy market is concentrated, with a few large players. The top ten competitors in the market made up to 53.81% of the total market in 2021. Novartis AG was the largest competitor with 14.57% share of the market, followed by F. Hoffmann-La Roche Ltd with 7.99%, Gilead Sciences Inc. with 7.55%, Astellas Pharma Inc. with 6.11%, Biogen Inc. with 3.81%, UniQure NV with 3.64%, REGENXBIO Inc. with 3.26%, Bristol-Myers Squibb with 2.84%, BioMarin Pharmaceuticals Inc. with 2.33% and Jazz Pharmaceuticals Inc. with 1.71%.

The top opportunities in the gene therapy market by vector will arise in the viral vector market, which will gain $14,868.9 million of global annual sales by 2027. The top opportunities in the gene therapy market by application will arise in the oncology market, which will gain $7,080.0 million of global annual sales by 2027. The top opportunities in the gene therapy market by end users will arise in the biopharmaceutical companies market, which will gain $8,883.0 million of global annual sales by 2027. The top opportunities in the gene therapy market by gene therapy will arise in the somatic cell therapy market, which will gain $15,839.6 million of global annual sales by 2027. The gene therapy market size will gain the most in the USA at $4,612.0 million.

Market-trend-based strategies for the gene therapy market include growing investments and manufacturing facility expansion, use of tetracycline-enabled self-silencing adenovirus (TESSA) technology, launch of cell and gene therapy platforms, partnerships and collaborations, rising focus on gene editing and strategic mergers and acquisitions.

Player-adopted strategies in the gene therapy industry include enhancing business operations through securing regulatory approvals, strengthening business activities through strategic collaborations and partnerships, expanding business capabilities through strategic acquisitions and strengthening operational capabilities through business expansions.

To take advantage of the opportunities, the publisher recommends the gene therapy companies to focus on investments in manufacturing facility expansion, focus on use of tetracycline-enabled self-silencing adenovirus (TESSA) technology, increase focus on gene editing, expand in emerging markets, continue to focus on developed markets, focus on partnerships and collaborations, focus on mergers and acquisitions, provide competitively priced offerings, participate in trade shows and events, continue to use B2B promotions, continue to target fast-growing end-users, and focus on fast-growing applications.